— Know what they know.
Not Investment Advice

ABCL NASDAQ

AbCellera Biologics Inc.
1W: -11.4% 1M: -28.3% 3M: +27.2% YTD: +54.2% 1Y: +3.5% 3Y: -32.6% 5Y: -67.6%
$5.29
+0.04 (+0.76%)
 
Weekly Expected Move ±13.5%
$4 $5 $5 $6 $7
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 35 · $1.6B mcap · 205M float · 3.90% daily turnover · Short 51% of daily vol
Smart Money Score
Moderate 50
Insider+$0.9M
Congress
ETF Holdings
Key Statistics
Market Cap$1.6B
52W Range2.745-8.44
Volume5,822,953
Avg Volume7,990,258
Beta1.15
Dividend
Analyst Ratings
10 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOCarl Hansen
Employees562
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-11
150 W 4th Ave
Vancouver, BC V5Y 0A1
CA
604 559 9005
About AbCellera Biologics Inc.

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

Recent Insider Trades

NameTypeSharesPriceDate
Sandor Victor A-Award 152,207 $7.85 2026-07-01
Seely Lynn A-Award 152,207 $7.85 2026-07-01
Seely Lynn 0 2026-06-30
Quake Stephen A-Award 111,701 $5.27 2026-06-11
Montalbano John S. A-Award 111,701 $5.27 2026-06-11

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms